RxDoctor Payments Data

Michael McRae

Family Medicine · Boise, IDNPI 1043745805

Payments from drug & device makers

$2,709in general payments, 2019–2025

Across 42 payments — averaging $64.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Tandem Diabetes Care, Inc.$301
  • Abbott$300
  • Corcept Therapeutics$234
  • Insulet Corporation$198
  • Dexcom, Inc.$135
  • plus $71 from 3 others

What the payments were for

  • Travel & lodging$1,02338%
  • Food & beverage$1,67462%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,709 in reported general payments places this provider in the 85th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$45,171
Medicare patients
194
Services billed
862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$240,798
MounjaroTirzepatide144$198,327
TrulicityDulaglutide124$192,743
JardianceEmpagliflozin64$94,633
EliquisApixaban78$94,291
GlyxambiEmpagliflozin/Linagliptin28$38,647
XareltoRivaroxaban23$26,412
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$25,476
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$19,409
FarxigaDapagliflozin Propanediol14$18,084
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$16,253
Repatha SureclickEvolocumab15$14,492
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$11,458
Humalog Kwikpen U-100Insulin Lispro20$6,948
Novolog FlexpenInsulin Aspart19$6,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$391,071268 claims
Novo NordiskOzempic$38$240,798166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 803 family medicine providers in Idaho.

Other family medicine in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →